[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100462505":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":38,"centralContacts":43,"locations":51,"responsibleParty":71,"collaborators":74,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":85,"sex":91,"minAge":92,"maxAge":31,"enrollmentInfo":93,"targetDuration":31,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":31,"overallStatus":53,"whyStopped":31,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"Central Hospital, Nancy, France","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Amoxicillin","EXPERIMENTAL","Each patient will receive the IV antibiotic required to treat the infection, and after the proper duration of the IV antibiotic is over, the patient will receive a few days of the oral version of the same antibiotic.",[13],"Drug: Amoxicillin",{"label":15,"type":10,"description":11,"interventionNames":16},"Ofloxacin",[17],"Drug: Ofloxacin",{"label":19,"type":10,"description":11,"interventionNames":20},"Levofloxacin",[21],"Drug: Levofloxacin",{"label":23,"type":10,"description":11,"interventionNames":24},"Sulfamethoxazole trimethoprim",[25],"Drug: Sulfamethoxazole trimethoprim",[27,32,34,36],{"type":28,"name":9,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Each patient will receive the proper antibiotic to treat the infection, first intravenously, then orally",[9],null,{"type":28,"name":19,"description":29,"armGroupLabels":33,"otherNames":31},[19],{"type":28,"name":15,"description":29,"armGroupLabels":35,"otherNames":31},[15],{"type":28,"name":23,"description":29,"armGroupLabels":37,"otherNames":31},[23],[39],{"name":40,"affiliation":41,"role":42},"Niasha MICHOT, MD","CHRU Nancy","PRINCIPAL_INVESTIGATOR",[44,48],{"name":40,"role":45,"phone":46,"phoneExt":31,"email":47},"CONTACT","+33383155108","n.michot@chru-nancy.fr",{"name":49,"role":45,"phone":31,"phoneExt":31,"email":50},"Elise Pape","e.pape@chru-nancy.fr",[52],{"facility":41,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"RECRUITING","Vandœuvre-lès-Nancy","Lorraine","54500","France","FR",{"type":60,"coordinates":61},"Point",[62,63],6.17114,48.66115,{"lat":63,"lon":62},[66,67],{"name":40,"role":45,"phone":46,"phoneExt":31,"email":47},{"name":68,"role":45,"phone":69,"phoneExt":31,"email":70},"Julie LECOMTE","+33383155278","ju.lecomte@chru-nancy.fr",{"type":42,"investigatorFullName":72,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"MICHOT Niasha","Principal Investigator",[75,77,80],{"name":76,"class":6},"Société Francophone Nutrition Clinique et Métabolisme",{"name":78,"class":79},"FIlière des Maladies rares Abdomino-THOraciques","UNKNOWN",{"name":81,"class":82},"Fresenius Kabi","INDUSTRY","100462505","phase-1-absorption-of-antibiotics-with-high-oral-bioavailability-in-short-bowel-syndrome-100462505",false,"NCT05302531","Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome","Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome : a Monocentric Pilot Study","GRAAL","Inclusion Criteria:\n\n* Short bowel syndrome\n* Treated for a documented infection with antibiogram by amoxicillin (+\u002F- clavulanic acid)or ofloxacin or levofloxacin or sulfamethoxazole\u002Ftrimethoprim\n* Hospitalized in the Nutritional Assistant Unit or the Infectiology Unit of the Regional University Hospital of Nancy\n* Affiliated to a social security system\n* Having received an physical examination before entering study\n* Having received full information regarding the study organization and having signed the informed consent\n\nExclusion Criteria:\n\n* Patient at risk of worsening their oral absorption abilities during study\n* Patient requiring dialysis\n* Women of childbearing age without efficient birth control\n* Allergy to any of the drugs tested\n* Person concerned by Articles L. 1121-5, L. 1121-7 et L1121-8 of the Code of public health\n* Person deprived of liberty or person undergoing psychiatric care pursuant to articles L. 3212-1 et L. 3213-1","ALL","18 Years",{"count":94,"type":95},10,"ESTIMATED","INTERVENTIONAL",[98],"PHASE1","The purpose of this study is to assess the drug absorption of oral antibiotics in patients with short bowel syndrome.",[101,102],"Short Bowel Syndrome","Infection, Bacterial","2024-08-28",{"date":105,"type":106},"2024-08-29","ACTUAL",{"date":108,"type":106},"2022-12-09",{"date":110,"type":95},"2025-02",{"name":5,"class":6},1]